Patient P-01765
Therapy response
Unstable
Tolerance
Stable
GI state
Stable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
92%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 48 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 50 SC-12 recommended — Supportive Compound SC-12
- Day 51 Patient accepted — Started SC-12 in the companion
- Day 57 GI symptom burden −22% vs expected — Supportive Compound SC-12
- Day 63 Tolerance state changed — Unstable → Improving
- Day 72 ME-01 recommended — Monitoring Escalation ME-01
- Day 73 Patient accepted — Started ME-01 in the companion
- Day 76 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 48.
Primary contributors, last 14 days
- Inflammatory activity-6
- GI instability+4
- Treatment adherence-4
- Nutritional resilience-3
- Toxicity-2
What helped?
- Supportive Compound SC-12Day 50Result: symptom burden −22%
- Monitoring Escalation ME-01Day 72Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 56 and rising
- WearableSleep 5.6 h, below personal baseline
- Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable2,507 steps/day
- WearableShort sleep window
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 34/100
- Daily logFibre intake low in recent food logs
- Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 44
- Inflammatory signalling ↓45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 34/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 38 ms
- Sleep
- 5.6 h
- Steps
- 1,902
- Resting HR
- 82 bpm
Daily log: GI score 56, nutritional resilience 41, adherence 45.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01564 | 48% | S14 | ME-01 | improved | 39 |
| P-01656 | 47% | S14 | ME-01 | improved | 41 |
| P-01728 | 46% | S14 | SC-12 | improved | 41 |
| P-01834 | 46% | S14 | NP-02 | improved | 44 |
| P-01394 | 45% | S05 | SC-12 | improved | 44 |
| P-01655 | 45% | S14 | GI-04 | no change | 29 |
| P-01356 | 44% | S14 | GI-04 | improved | 42 |
| P-01436 | 44% | S14 | GI-04 | improved | 38 |
| P-01517 | 44% | S06 | NP-02 | improved | 27 |
| P-01556 | 44% | S14 | GI-04 | improved | 44 |
| P-01402 | 43% | S04 | GI-04 | improved | 37 |
| P-01409 | 43% | S14 | SC-12 | improved | 41 |